康惠制药：因业绩补偿纠纷申请仲裁，涉案金额2.66亿元

Core Viewpoint - 康惠制药 is pursuing arbitration against 来新胜 for failing to meet profit commitments related to the acquisition of 山东友帮, with a significant compensation amount still owed [1] Summary by Relevant Sections Acquisition Details - 康惠制药 acquired 51% of 山东友帮 from 来新胜 for 32.64 million yuan in September 2020 [1] - 来新胜 committed to a cumulative net profit of no less than 35 million yuan from 2021 to 2023 [1] Performance and Compensation - 山东友帮 did not meet the promised performance, leading to a compensation obligation of 269 million yuan from 来新胜 [1] - As of now, 来新胜 still owes 266 million yuan after paying 2.8 million yuan in compensation [1] Legal Proceedings - 康惠制药 has applied for arbitration with the 咸阳仲裁委, which was accepted on November 13 [1] - The case has not yet gone to court, making it difficult to assess the impact on the company's profits [1]